ad image

Forty Seven Inc.

1 / 1
Gilead Sciences
M&A

Gilead to Acquire Forty Seven for $4.9 Billion

Gilead Sciences

PR-M03-20-NI-003Mar 02, 2020
Forty Seven Inc.
Strategic Collaboration

Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer

Forty Seven Inc.

PR-M01-18-NI-043Jan 16, 2018
Forty Seven Inc.
Immuno-Oncology

Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer

Forty Seven Inc.

PR-M01-18-NI-042Jan 16, 2018
1 / 1